Advertisement
Canada markets close in 1 hour 52 minutes
  • S&P/TSX

    21,866.86
    -144.86 (-0.66%)
     
  • S&P 500

    5,069.27
    -1.28 (-0.03%)
     
  • DOW

    38,465.98
    -37.71 (-0.10%)
     
  • CAD/USD

    0.7296
    -0.0024 (-0.33%)
     
  • CRUDE OIL

    82.49
    -0.87 (-1.04%)
     
  • Bitcoin CAD

    88,660.04
    -2,929.43 (-3.20%)
     
  • CMC Crypto 200

    1,401.62
    -22.48 (-1.58%)
     
  • GOLD FUTURES

    2,337.80
    -4.30 (-0.18%)
     
  • RUSSELL 2000

    1,995.41
    -7.23 (-0.36%)
     
  • 10-Yr Bond

    4.6600
    +0.0620 (+1.35%)
     
  • NASDAQ

    15,711.36
    +14.72 (+0.09%)
     
  • VOLATILITY

    15.72
    +0.03 (+0.19%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6820
    -0.0016 (-0.23%)
     

How Wall Street Reacted to Berkshire Hathaway Investment in Teva

How Wall Street Reacted to Berkshire Hathaway Investment in Teva

After Berkshire Hathaway (BRK) disclosed its investment of $358 million in Teva Pharmaceuticals (TEVA) on February 14, 2018, in a regulatory filing at the end of 4Q17, Wall Street analysts have had a lot to say about the investment. Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day. The PowerShares International Dividend Achievers Portfolio (PID) rose ~1.3% on February 15, 2018.